Oxygen Biotherapeutics, Inc. Share Price Nasdaq
Equities
US69207P2092
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 6.21M 518M |
---|---|---|---|---|---|
Net income 2024 * | -19M -1.59B | Net income 2025 * | -18M -1.5B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.39
x | P/E ratio 2025 * |
-0.85
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.65% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 50 | 14/21/14 | |
Director of Finance/CFO | 69 | 11/01 | |
Stuart Rich
CTO | Chief Tech/Sci/R&D Officer | 74 | 15/21/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gerry Proehl
CHM | Chairman | 65 | 04/14/04 |
June Almenoff
BRD | Director/Board Member | 67 | 25/21/25 |
Declan Doogan
BRD | Director/Board Member | 72 | 25/21/25 |
1st Jan change | Capi. | |
---|---|---|
+18.97% | 45.34B | |
+41.98% | 40.42B | |
-10.06% | 37.92B | |
+31.15% | 31.75B | |
-7.79% | 27.71B | |
+13.32% | 26.52B | |
+43.05% | 13.96B | |
+31.28% | 12.44B | |
-7.41% | 11.26B |